Back Back to portfolio

Ochre Bio

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications.

ochre-bio.com

Founded In

2019

Fund

Hoxton II

Headquarters

London, UK

Invested In

2020

Hoxton Partners

Rob Kniaz